drugset / Trial / NCT05593549

Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction

NCT05593549

Phase 0 Recruiting 60 enrolled Medical College of Wisconsin
RandomizedParallel-groupDouble-blindBasic science

Summary

The goal of this clinical trial is to examine the role of autophagy on microvascular function in adults with Type 2 Diabetes. The main question it aims to answer are: * Does presence of Type 2 Diabetes reduce autophagy and impair microvascular function? * Does exposure to high glucose impair autophagy and subsequently microvascular function? Participants will undergo 2 study days. The primary outcome will be in vivo microvascular function testing. Following the first study day participants will undergo either supplementation with trehalose, an autophagy activator, or placebo for 14 days. The second study day will test in vivo microvascular function.

Timeline

Start
2023-01-01
Primary completion
2028-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Trehalose Small molecule 10 g Oral